Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 contains Perspective Therapeutics’ corporate presentation.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Exhibit 99.1 contains Perspective Therapeutics’ corporate presentation
- Investor-relevant information is contained in the presentation rather than the 8-K body
- Filing signed August 3, 2026 by CFO Joel Sendek
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation highlights Perspective’s ²¹²Pb radiopharmaceutical pipeline targeting neuroendocrine tumors, melanoma, and broader solid tumors
- VMT-α-NET Phase 1/2a data cover 68 treated patients, with responses deepening over time and durable disease control across doses
- VMT-α-NET profile supports a potential registration study at the current dose level, advancing the lead program toward pivotal development
- VMT01 showed preliminary anti-tumor activity at the 3.0 mCi dose in melanoma, supporting continued clinical development
- PSV359 demonstrated improved tumor retention in an ongoing Phase 1/2a solid-tumor trial, supporting its therapeutic potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.